13F Holdings
中文EN

MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1823239 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.8%
TTM net income YoY45.8%
TTM EPS YoY47.6%
Revenue 3-yr CAGR-20.2%
Net income 3-yr CAGR—

Margins

Gross margin39.1%
Operating margin-45.4%
Net margin-30.8%
FCF margin-5.9%
EBITDA margin-35.1%

Returns

ROE-29.8%
ROA-9.1%
ROIC (approx.)-27.0%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets43.3%
Debt / equity0.75x
Current ratio4.66x
Interest coverage-4.57x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue3.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$185.74M$259.19M$288.94M$883.00M$799.24M
Cost of revenue$151.75M$150.88M$148.74M$168.96M$140.56M
Gross profit$33.99M$108.31M$140.20M$714.04M$658.68M
R&D expense$17.40M$19.22M$17.28M$18.37M$15.22M
SG&A expense$145.12M$161.77M$151.39M$129.26M$100.06M
Operating income-$215.27M-$235.62M-$31.65M$574.22M$554.64M
Interest expense$26.99M$47.70M$45.89M$20.41M$30.26M
Pretax income-$234.97M-$261.48M$617.74M$551.47M$530.76M
Income tax-$4.21M-$1.86M$756.11M$60.81M$61.52M
Net income-$130.77M-$144.85M-$119.03M$220.21M$182.04M
EBITDA-$191.71M-$214.76M-$18.75M$581.78M$561.06M
EPS (basic)-0.90-1.05-0.901.671.59
EPS (diluted)-0.90-1.05-0.901.671.56
Weighted avg. shares (diluted)144.36M137.91M131.92M255.32M257.80M
Balance sheet
Cash & equivalents$216.89M$322.40M$574.96M$632.14M$551.27M
Receivables$25.50M$38.52M$54.60M$138.62M$117.51M
Inventory$40.49M$50.08M$51.40M$43.15M$51.56M
Current assets$296.25M$429.15M$699.91M$847.90M$740.04M
PP&E, net$151.48M$164.47M$162.90M$52.69M$46.33M
Goodwill$129.43M$159.88M$326.03M$283.67M$152.77M
Intangibles$151.54M$194.96M$220.99M$216.66M$117.57M
Total assets$770.58M$1.01B$1.49B$2.28B$1.92B
Current liabilities$44.92M$56.97M$87.47M$110.14M$93.78M
Short-term debt$5.44M$5.44M$5.44M$5.44M$6.00M
Long-term debt$286.33M$290.49M$518.71M$522.00M$524.59M
Total debt$291.77M$295.93M$524.15M$527.44M$530.59M
Total liabilities$397.87M$431.04M$697.57M$1.38B$1.37B
Shareholders' equity$212.38M$325.29M$416.75M$545.22M$315.50M
Net debt$74.88M-$26.47M-$50.81M-$104.70M-$20.68M
Cash flow statement
Operating cash flow-$57.57M$7.46M$126.22M$535.98M$368.57M
Capital expenditure$13.15M$29.66M$65.55M$17.09M$14.85M
Free cash flow-$70.72M-$22.19M$60.67M$518.89M$353.72M
Investing cash flow-$31.41M-$24.32M-$122.31M-$267.61M$105.66M
Financing cash flow-$16.50M-$235.71M-$61.09M-$187.50M-$159.05M
Depreciation & amortization$23.56M$20.85M$12.90M$7.57M$6.41M
Stock-based compensation$30.17M$49.41M$34.59M$18.67M$10.46M
Share buybacks———$0$0

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.